1




PRESS RELEASE
Lyon, December 8, 2025




Number of Shares and Voting Rights of
ADOCIA as of December 8th, 2025

7:30 pm CET - Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and
article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés
Financiers, or “AMF”), ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne,
69003 Lyon (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company
focused on the research and development of innovative therapeutic solutions for the treatment of
diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of
December 8th, 2025.


Total number of Total number of
Total number of
Month Date theoretical voting rights exercisable voting rights
outstanding shares
(1) (2)

December 12/08/2025 19,568,909 21,675,991 21,652,769




(1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds.
In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to
which voting rights are attached, including shares whose voting rights have been suspended.

(2) The total number of exercisable voting rights is calculated without taking into account the shares with suspended voting
rights, in this case, shares held by the Company in the context of a liquidity agreement. It is provided for the information of
the public, in accordance with the AMF recommendation of July 17, 2007.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic
solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms:
1) BioChaperone® for the stabilization and enhancement of peptide formulations and combinations; 2)
AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell
transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoXLongTM, a
long-acting peptide platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia
is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).




Contact

Adocia Ulysse Communication
Olivier Soula Adocia Media and Investor Relations
CEO Bruno Arabian
contactinvestisseurs@adocia.com Nicolas Entz
Tel: +33 4 72 610 610
adocia@ulysse-communication.com
www.adocia.com + 33 (0)6 87 88 47 26